8-K: INVO Bioscience Reports Record First Quarter Revenue Growth of 353% and Improved Adjusted EBITDA

INVO Bioscience announced a 353% increase in revenue for the first quarter of 2024, alongside a significant improvement in adjusted EBITDA.

Summary

• INVO Bioscience reported a record first quarter in 2024, with revenue reaching $1,576,286, a 353% increase compared to $348,025 in the same period last year.
• Clinic revenue saw a substantial 417% increase, totaling $1,537,199, up from $297,381 in the first quarter of 2023.
• Total revenue from all clinics, including those accounted for under the equity method, was $1,869,513, a 189% increase from $646,707.
• Operating expenses decreased slightly to $2.5 million from $2.6 million, which included $80,000 related to the merger agreement with NAYA Biosciences.
• The company's net loss was $(1.6) million, an improvement from $(2.6) million in the prior year.
• Adjusted EBITDA improved significantly to $(0.5) million, compared to $(1.7) million in the first quarter of 2023, including merger transaction costs.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the significant revenue growth and improvement in adjusted EBITDA. However, the ongoing net loss and the need for additional funding temper the overall optimism.

Positives

• The company experienced a significant 353% increase in revenue compared to the same quarter last year.
• Clinic revenue saw a substantial 417% increase, indicating strong performance in their core business.
• The company's adjusted EBITDA improved by $1.2 million year-over-year, showing progress towards profitability.
• Operating expenses decreased slightly, demonstrating effective cost management.
• The net loss decreased by $1 million compared to the same quarter last year.

Negatives

• The company still reported a net loss of $(1.6) million for the quarter.
• Adjusted EBITDA remains negative at $(0.5) million, although it has improved significantly.
• The merger with NAYA Biosciences is still subject to closing conditions, including shareholder approval and additional funding.

Risks

• The merger with NAYA Biosciences is not yet finalized and is subject to various closing conditions, including shareholder approval and securing additional funding.
• The company needs to raise $5,000,000 through the sale of Series A Preferred Stock, plus additional funding to support operations through the merger and for twelve months after closing.
• The company's ability to achieve break-even or profitability is dependent on continued revenue growth and cost management.
• The company is still operating at a loss, although the loss has decreased.

Future Outlook

The company aims to achieve break-even or profitability with current operations in 2024, excluding the proposed merger with NAYA. They also plan to acquire additional clinics and open new INVO Centers to expand access to fertility care.

Management Comments

• We are pleased with the progress we have made at INVO, reporting record first quarter 2024 revenue with of growth of 353% compared to the first quarter of 2023, and a substantial $1.2 million improvement in our adjusted EBITDA, commented Steve Shum, CEO of INVO.
• The strategic initiatives we have implemented to capture a greater share of the total fertility cycle revenue and profit through the transformation of INVO from a medical device company into an innovative healthcare services company are starting to bear fruit.
• We are potentially on track to achieve our stated goals of reaching break-even or profitability with our current operations (excluding the proposed merger with NAYA) in 2024.
• We also remain excited about our position in the fertility market, the opportunities we have to acquire additional clinics and to open new INVO Centers, and our ongoing efforts to make advanced fertility care more accessible and inclusive to people around the world.
• As reflected in the recent merger amendment and subject to meeting all agreed terms, INVO and NAYA remain committed to completing the merger between our two companies, creating a company uniquely positioned in both the fertility and oncology space, commented Shum.

Industry Context

The announcement reflects a broader trend in the fertility industry towards expanding access to care through clinic acquisitions and innovative technologies like INVOcell. The merger with NAYA Biosciences also indicates a move towards diversification into other healthcare sectors.

Comparison to Industry Standards

• The 353% revenue growth is significantly higher than the average growth rate for fertility clinics, which typically see single-digit to low double-digit growth annually. Companies like Boston IVF and CCRM Fertility, while larger, do not typically report such high quarterly growth rates.
• The improvement in adjusted EBITDA from $(1.7) million to $(0.5) million is a positive sign, but the company still needs to achieve positive EBITDA to be in line with industry leaders. Many established fertility clinic chains aim for EBITDA margins of 15-25%.
• The focus on intravaginal culture (IVC) with INVOcell is a differentiator, as most clinics rely on traditional IVF. This technology could provide a competitive advantage if it proves to be more cost-effective and accessible.

Stakeholder Impact

• Shareholders will be impacted by the potential merger with NAYA Biosciences and the need for additional funding.
• Employees may be affected by the merger and any resulting changes in the company's structure.
• Customers will benefit from the company's efforts to expand access to fertility care.
• Suppliers and creditors may be impacted by the company's financial performance and the merger.

Next Steps

• The company is working on an update to their Proxy S-4.
• They plan to schedule a stockholders meeting as soon as the SEC review of their filing is complete.
• The company will continue to pursue the merger with NAYA Biosciences.
• They will continue to explore opportunities to acquire additional clinics and open new INVO Centers.

Key Dates

Keywords

INVO Bioscience, Fertility, IVF, INVOcell, Revenue Growth, Adjusted EBITDA, Merger, Healthcare Services, Clinic Revenue, NAYA Biosciences